Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System

European Journal of Haematology

Volumn 78, Issue 3, 2007, Pages 227-234

  Sagaster, V ^a   Kaufmann, H ^a   Odelga, V ^a   Ackermann, J ^a   Gisslinger, H ^a   Rabitsch, W ^a   Zojer, N ^b   Ludwig, H ^b   Nosslinger T ^c   Zielinski, C ^a   Drach, J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Wilhelminenspital ^*  (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Age; International Staging System stage; Molecular cytogenetics; Multiple myeloma; Prognosis

Indexed keywords

AGE DISTRIBUTION; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME DELETION 13; CHROMOSOME TRANSLOCATION 13; CHROMOSOME TRANSLOCATION 14; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; INTERPHASE; MALE; MOLECULAR GENETICS; MULTIPLE MYELOMA; PLOIDY; PRIORITY JOURNAL; STANDARD; SURVIVAL TIME;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERNATIONALITY; INTERPHASE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 33847028373     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00807.x     Document Type: Article

References (37)

1. Edwards BK, Brown ML, Wingo PA et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Ntl Cancer Inst 2005;97:1407-27.
2. Ludwig H, Fritz E, Friedl HP. Epidemiologic and age-dependent data on multiple myeloma in Austria. J Natl Cancer Inst 1982;68:729-33.
3. Devesa SS, Silverman DT, Young JL Jr, Pollack ES, Brown CC, Horm JW, Percy CL, Myers MH, McKay FW, Fraumeni JF Jr. Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst 1987;79:701-70 (Review).
4. Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 1992;6:225-47 (Review).
5. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-87 (Review).
6. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003;4:557-63.
7. Zandecki M, Lai JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 1996;94:217-27 (Review).
8. Drach J, Schuster J, Nowotny H et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 1995;55:3854-9.
9. Fonseca R, Barlogie B, Bataille R et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546- 58.
10. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250-6.
11. Fonseca R, Blood E, Rue M et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569-75.
12. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Groupe Francais de Cytogenetique Hematologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001;98:2229-38.
13. Zojer N, Konigsberg R, Ackermann J et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000;95:1925-30.
14. Fonseca R, Debes-Marun CS, Picken EB et al. The recurrent IgH translocations are highly associated with non-hyperdiploid variant multiple myeloma. Blood 20003;102:2562-7.
15. Mileshkin L, Biagi JJ, Mitchell P et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003;102:69-77.
16. Garcia-Sanz R, Gonzalez-Fraile MI, Mateo G et al. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer 2004;112:884-9.
17. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
18. Drach J, Angerler J, Schuster J et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995;86:3915-21.
19. Ackermann J, Meidlinger P, Zojer N, Gisslinger H, Ludwig H, Huber H, Drach J. Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance. Br J Haematol 1998;103:1161-3.
20. Kaufmann H, Ackermann J, Baldia C et al. Both IgH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 2004;18:1879-82.
21. Drach J, Ackermann J, Baldia C et al. The chromosomal pattern 14q-translocation plus 13q deletion is characteristic for multiple myeloma after a preceding monoclonal gammopathy of undetermined significance. Haematologica 2005;90 (Suppl. 1):71 (abstractPO.106).
22. Greipp PR, San Miguel J, Durie BG et al. International Staging System for multiple myeloma. J Clin Oncol 2005;23:3412-20.
23. Ferrara F, Mirto S, Zagonel V, Pinto A. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. Leuk Lymphoma 1998;29:375-82.
24. Paulsson K, Sall T, Fioretos T, Mitelman F, Johansson B. The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. Cancer Genet Cytogenet 2001;130:160-5.
25. Frohling S, Kayser S, Mayer C, Miller S, Wieland C, Skelin S, Schlenk RF, Dohner H, Dohner K, ML Study Group Ulm. Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia. Haematologica 2005;90:194-9.
26. Stark GL, Wood KM, Jack F et al. Hodgkin's disease in he elderly: a population-based study. Br J Haematol 2002;119:432-40.
27. Proctor SJ, Rueffer JU, Angus B et al. Hodgkin's disease in the elderly: current status and future directions. Ann Oncol 2002;13:133-7.
28. Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996;93:345-51.
29. Ross F, Ibrahim AH, Vilain-Holmes A et al. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 2005;19:1634-42.
30. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002;99:2185-91.
31. Dewald GW, Therneau T, Larson D, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005;106:3553-8.
32. Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006;20:1610-7.
33. Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:1844-54.
34. Child JA, Morgan GJ, Davies FC et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
35. Riccardi A, Mora O, Brugnatelli S et al. Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 1998;77:485-91.
36. Desikan R, Barlogie B, Sawyer J et al. Results of highdose therapy for 1000 patients with multiple myeloma: durable complete remission and superior survival in the absence of chromosome 13 abnormalities. Blood 2000;95:4008-10.
37. Shaughnessy J, Jacobson J, Sawyer J et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensure long-term survival in myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 2003;101:3849-56.